Recent News

• 04.03.2025 - Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
• 03.07.2025 - Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
• 02.14.2025 - Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
• 02.04.2025 - Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
• 01.23.2025 - Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Recent Filings

• 03.24.2025 - S-3 Registration statement under Securities Act of 1933
• 03.18.2025 - 8-K Current report
• 03.18.2025 - PRE 14A Other preliminary proxy statements
• 03.17.2025 - D Notice of Exempt Offering of Securities
• 03.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.10.2025 - 8-K Current report
• 03.10.2025 - EX-99.1 EX-99.1
• 02.14.2025 - EX-99.1 EX-99.1
• 02.14.2025 - 8-K Current report